Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark.
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Cancer Imaging. 2022 Sep 3;22(1):44. doi: 10.1186/s40644-022-00484-0.
We aimed to evaluate the prevalence of incidental Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT (SSTR PET/CT) findings, their clinical significance in the need for follow-up, and their risk of malignancy.
Studies reporting incidental SSTR PET/CT findings were systematically searched in PubMed, Cochrane, Embase and Web of Science literature published prior to 1 of May 2020. Studies were filtered by two independent readers for eligibility based on title and abstract, and subsequently on full text. The main exclusion criteria were: 1) pathological findings that matched scan indication, 2) known organ specific disease and/or incidental findings confirmed on other scan modality prior to SSTR PET/CT, 3) lack of diagnosis and/or follow up, and 4) results published in proceedings or conference abstracts.
Twenty-one studies, comprising a total of 2906 subjects, were eligible for the analysis. Studies included were retrospective cohort studies on incidental SSTR PET/CT findings in a specific organ (n = 2888, 7/21) or case reports (n = 18, 14/21). A total of 133 subjects had incidental SSTR PET/CT findings. Incidental findings were predominantly seen in the thyroid gland (n = 65), spine (n = 30), brain (n = 26) and breast (n = 6). Seventeen of 133 (13%) incidental findings were malignant on final diagnosis. Incidental breast findings were associated with the highest risk of malignancy (67%). In the thyroid, incidental SSTR uptake was caused by malignancy in 8%, all presenting as focal uptake. The lowest risk was seen in the spine with a malignancy rate of 3% in patients with incidental SSTR uptake and benign cases were interpreted as vertebral hemangiomas on CT. Incidental SSTR PET/CT findings in other locations were of malignant etiology in two out of six cases (33%) and should be evaluated individually.
The most incidental SSTR PET/CT findings were found in the thyroid gland, spine, and brain. The risk of malignancy was greatest in incidental SSTR PET/CT findings in the breast, cranially, and thyroid gland. The results of the present study can prove useful in the interpretation of atypical findings on SSTR PET/CT and in the counseling of clinicians.
评估偶然发现的 Ga-DOTA 缀合生长抑素受体靶向肽 PET/CT(SSTR PET/CT)发现的发生率、其在随访需求中的临床意义,以及恶性肿瘤的风险。
系统检索了截至 2020 年 5 月 1 日前在 PubMed、Cochrane、Embase 和 Web of Science 文献中发表的报告偶然 SSTR PET/CT 发现的研究。两名独立读者根据标题和摘要筛选研究是否符合纳入标准,然后根据全文进一步筛选。主要排除标准为:1)与扫描指征相匹配的病理发现;2)已知器官特异性疾病和/或在 SSTR PET/CT 之前在其他扫描方式上证实的偶然发现;3)缺乏诊断和/或随访;4)研究结果以论文或会议摘要形式发表。
共纳入 21 项研究,共计 2906 例患者。纳入的研究为特定器官偶然 SSTR PET/CT 发现的回顾性队列研究(n=2888,21 项研究中的 7 项)或病例报告(n=18,21 项研究中的 14 项)。共 133 例患者偶然发现 SSTR PET/CT 异常。偶然发现的异常主要发生在甲状腺(n=65)、脊柱(n=30)、脑(n=26)和乳腺(n=6)。最终诊断 133 例偶然发现中,17 例(13%)为恶性。偶然发现的乳腺异常恶性风险最高(67%)。甲状腺的 SSTR 摄取偶发由恶性引起,占 8%,均表现为局灶性摄取。脊柱的恶性风险最低,占 3%,偶然摄取 SSTR 的患者中良性病例被 CT 诊断为椎体血管瘤。其余 6 例偶然 SSTR PET/CT 发现中,有 2 例(33%)为恶性病因,需要单独评估。
最常见的偶然 SSTR PET/CT 发现是在甲状腺、脊柱和脑部。乳腺、颅部和甲状腺偶然 SSTR PET/CT 发现的恶性风险最高。本研究的结果可有助于解释 SSTR PET/CT 上不典型发现,并为临床医生提供咨询。